Table 2.
# | area | RJ | LR | BI* | PGL-I* | sex | age* |
---|---|---|---|---|---|---|---|
1 | Bangladesh | BL | RR | 2+ | 0.95 | male | 36 |
2 | Bangladesh | BL | RR | 2+ | 0.27 | female | 39 |
3 | Bangladesh | BL | RR | 0 | 1.82 | male | 36 |
4 | Bangladesh | BL | RR | 2+ | 1.17 | male | 32 |
5 | Brazil | BL | RR | 3.2+ | 0,43 | male | 35 |
6 | Brazil | BL | RR | 2.42+ | 0.07 | male | 29 |
7 | Brazil | BL | RR | 4.28+ | 1.02 | female | 42 |
8 | Nepal | BT | RR | 0.25+ | 0.07 | female | 40 |
9 | Ethiopia | BB | RR | 0 | 0.15 | male | 33 |
10 | Netherlands | BL | RR | 5+ | 1.83 | male | 17 |
§Blood samples were collected from 10 patients at 3 time points: at diagnosis of leprosy in the absence of any clinical signs of reactions, at diagnosis of reactions and after treatment; * at recruitment before treatment.
RJ: Ridley Joplin classification; LR: Leprosy Reaction; RR: reversal reaction.
BI: bacterial index; PGL-I: OD at 450 nm in anti-PGL-I antibody ELISA (threshold for positivity: OD450 = 0.2).